Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STereotactic Ablative RadioTherapy in NEWly Synchronous and mEtachRonous (Oligo-persistence, Oligo-induced, Oligo-progression) Oncogene and Non Oncogene Addicted OLIGO-metastatic Non-small Cell Lung Cancer Patients

NCT06207292 is registered in ClinicalTrials.gov with Radiotherapy Oncology Centre "Santa Maria" Hospital as lead sponsor.

NCT NCT06207292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06207292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STereotactic Ablative RadioTherapy in NEWly Synchronous and mEtachRonous (Oligo-persistence, Oligo-induced, Oligo-progression) Oncogene and Non Oncogene Addicted OLIGO-metastatic Non-small Cell Lung Cancer Patients
Lead sponsor
Radiotherapy Oncology Centre "Santa Maria" Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
December 31, 2016
Completion date
December 31, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egf-r positive non-small cell lung cancer, metachronous metastasis, non small cell lung cancer, non small cell lung cancer metastatic, non-small cell adenocarcinoma, non-small cell lung cancer with mutation in epidermal growth factor receptor, non-small cell squamous lung cancer, nsclc, nsclc stage iv, nsclc stage iv without egfr/alk mutation, oligometastatic disease, synchronous metastases